Korean J Women Health Nurs.  2022 Jun;28(2):83-86. 10.4069/kjwhn.2022.05.10.

Gynecologic cancer clinical practice guidelines in Korea and current issues

• Kim J
• Son JH
• Kong TW
• Chang SJ

• KMID: 2535425
• DOI: http://doi.org/10.4069/kjwhn.2022.05.10

Reference

References

1. Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat. 2020; 52(2):335–350. https://doi.org/10.4143/crt.2020.206.

2. Ha HI, Chang HK, Park SJ, Lim J, Won YJ, Lim MC. The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry. Obstet Gynecol Sci. 2021; 64(5):444–453. https://doi.org/10.5468/ogs.21116.

3. Suh DH, Chang SJ, Song T, Lee S, Kang WD, Lee SJ, et al. Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. J Gynecol Oncol. 2018; 29(4):e56. https://doi.org/10.3802/jgo.2018.29.e56.

4. Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health. 2014; 14:150. https://doi.org/10.1186/s12905-014-0150-5.

5. Chiyoda T, Sakurai M, Satoh T, Nagase S, Mikami M, Katabuchi H, et al. Lymphadenectomy for primary ovarian cancer: a systematic review and meta-analysis. J Gynecol Oncol. 2020; 31(5):e67. https://doi.org/10.3802/jgo.2020.31.e67.

6. Coleridge SL, Bryant A, Kehoe S, Morrison J. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2021; 2(2):CD005343. https://doi.org/10.1002/14651858.CD005343.pub5.

7. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HW, Hermans RH, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018; 378(3):230–240. https://doi.org/10.1056/NEJMoa1708618.

8. Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(9):1274–1284. https://doi.org/10.1016/S1470-2045(17)30469-2.

9. Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021; 22(5):620–631. https://doi.org/10.1016/S1470-2045(21)00073-5.

10. Kim YM. PARP inhibitors get insurance benefits for 1st-line maintenance in ovarian cancer [Internet]. Seoul: Korea Biomedical Review: 2021 Sep 29 [cited 2022 May 9]. Available from: http://www.koreabiomed.com/news/articleView.html?idxno=12236.

11. Lee SW, Lee TS, Hong DG, No JH, Park DC, Bae JM, et al. Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. J Gynecol Oncol. 2017; 28(1):e12. https://doi.org/10.3802/jgo.2017.28.e12.

12. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271–289. https://doi.org/10.3322/caac.21349.

13. Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018; 379(20):1895–1904. https://doi.org/10.1056/NEJMoa1806395.

14. Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014; 370(8):734–743. https://doi.org/10.1056/NEJMoa1309748.